Drugmaker Mylan NV on Tuesday reported lower-than-expected quarterly revenue and failed to provide greater clarity on a potential revamp of the company’s strategy, sending its shares down 17 percent to a more than six-and-a-half year low.
Source:: Reuters – Business News